On Thursday, Piper Sandler initiated coverage on Tyra Biosciences (NASDAQ:TYRA) stock, a biopharmaceutical company, with an Overweight rating and a price target of $33.00.
The firm highlighted Tyra Biosciences' specialization in fibroblast growth factor receptor (FGFR) biology, which is anticipated to address the limitations of previous FGFR inhibitors.
Tyra Biosciences' leading drug candidate, TYRA-300, is currently in clinical development for metastatic urothelial carcinoma (mUC) and is expected to produce early Phase 1 data in the second half of 2024.
The drug is also planned to enter clinical trials for achondroplasia, a bone growth disorder, and non-muscle invasive bladder cancer (NMIBC) by the end of 2024 and the first half of 2025, respectively.
The investment firm is particularly optimistic about TYRA-300's potential in treating achondroplasia, suggesting that the drug could be a best-in-class option for this condition and other growth disorders, including hypochondroplasia. Piper Sandler projects that TYRA-300 could be approved and launched for use in urothelial carcinoma by 2027 and for achondroplasia by 2029.
Piper Sandler's revenue forecast for Tyra Biosciences is ambitious, with expectations that the company's revenue could grow to approximately $2.5 billion by 2035. The firm's analyst believes that the stock could approach the $33 price target as the company progresses with its clinical developments and potential market launches.
In other recent news, Tyra Biosciences has made significant strides in its clinical trials and drug development. The company completed the dose escalation part of its Phase 1/2 study, SURF301, marking a crucial development in its oncology treatments.
H.C. Wainwright raised the stock price target for Tyra Biosciences to $25.00, maintaining a Buy rating, reflecting the company's successful trials and revised near-term expense projections.
Furthermore, Tyra Biosciences presented promising preclinical data for its drug TYRA-300, a potential treatment for hypochondroplasia (HCH), at the Annual Achondroplasia & Skeletal Dysplasia Research Conference. The data demonstrated the drug's ability to increase long bone length and skull size in FGFR3 mutated mice.
TD Cowen also maintained its Buy rating on Tyra Biosciences, buoyed by these findings and the expected submission of an Investigational New Drug application for TYRA-300 in achondroplasia.
The company also welcomed Susan Moran, M.D., M.S.C.E., and S. Michael Rothenberg, M.D., Ph.D., as independent directors, strengthening its board. These recent developments reflect Tyra Biosciences' ongoing efforts to advance its drug pipeline and commitment to developing precision medicines for targeted oncology and genetically defined conditions.
InvestingPro Insights
In light of Piper Sandler's optimistic outlook on Tyra Biosciences, a glance at the real-time data and InvestingPro Tips can offer additional context for investors. Tyra Biosciences holds a market capitalization of $1.14 billion, suggesting a robust valuation in the biopharmaceutical sector. Despite not being profitable over the last twelve months, the company maintains a strong financial position, with more cash than debt on its balance sheet and liquid assets that exceed short-term obligations. This could provide the company with a cushion to navigate through its clinical development phase.
Moreover, the stock has been performing well in the market, trading near its 52-week high and delivering a strong return over the last three months. This positive price momentum aligns with Piper Sandler's coverage initiation and may reflect investor confidence in the company's drug pipeline. While Tyra Biosciences does not pay a dividend, indicating a reinvestment of earnings back into the company, analysts have revised their earnings upwards for the upcoming period, which could signal future growth potential.
For those seeking more in-depth analysis, there are additional InvestingPro Tips available to guide investment decisions. With a focus on the company's financial health and market performance, these insights can help investors better understand the investment landscape surrounding Tyra Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.